Use of Empagliflozin to Treat Prediabetes

Part of paid clinical trials in Corvallis, Oregon.

Sponsor
Oregon State University
Study ID
NCT05426525
Phase
PHASE4
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 59 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin — DRUG
    Participants will take 10mg empagliflozin per day for 2 weeks. Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.
  • Multivitamin-Placebo — DRUG
    Participants will take 1 multivitamin per day for 13 weeks.

Study Details

The overall purpose of this study is to identify how empagliflozin (a drug commonly used to treat type 2 diabetes) impacts skeletal muscle metabolic health among adults with prediabetes. Our aims are to: 1) Test the ability of empagliflozin to improve regulation of glucose metabolism (i.e., blood sugar) among overweight and obese individuals at risk for diabetes, and 2) Identify mechanisms to explain how empagliflozin may improve skeletal muscle glucose metabolism. We hypothesize empagliflozin will improve regulation of glucose metabolism due to changes in whole-body and skeletal muscle metabolism (e.g., increased rates of whole-body fat oxidation, evidence of impaired skeletal muscle mitochondrial respiratory function and increased energetic stress, lower accumulation of skeletal muscle lipids and improved skeletal muscle insulin signaling compared with placebo treatment).

Key Dates

Start date
Oct 13, 2022
Status verified
Jan 2026
Primary completion
May 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Empagliflozin
    Participants will be provided 10-25mg empagliflozin per day for 13 weeks.
  • Placebo Comparator: Multivitamin-Placebo
    Participants will be provided 1 multivitamin-placebo per day for 13 weeks.

Primary Outcome Measure

Insulin-stimulated glucose disposal [ Time Frame: Insulin-stimulated glucose disposal is measured before the start of the intervention (baseline) and during week 13 of the intervention. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon State UniversityCorvallisOregon97331-

Find similar trials in Corvallis, OR

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Oregon State University· Corvallis, OR

Related Studies